Glucose-specific Regulation of Aldose Reductase in Capan-1 Human Pancreatic Duct Cells In Vitro

Julia V. Busik,* Seth R. Hootman,* Caroline A. Greenidge,* and Douglas N. Henry†‡
*Department of Physiology and †Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan 48824

Abstract

Impaired pancreatic duct secretion is frequently observed in insulin-dependent diabetes mellitus (IDDM), although the cellular mechanism(s) of dysfunction remains unknown. Studies in other tissues have suggested that a hyperglycemia-induced decrease in Na,K-ATPase activity could contribute to the metabolic complications of IDDM and that increased polyol metabolism is involved in this response. The present studies examined the effects of glucose on Na,K-ATPase activity and on expression and activity of aldose reductase (AR), a primary enzyme of polyol metabolism, in Capan-1 human pancreatic duct cells. Increasing medium glucose from 5.5 to 22 mM caused a 29% decrease in Na,K-ATPase activity. The decrease was corrected by 100 μM sorbinil, a specific AR inhibitor. Increasing glucose from 5.5 to 110 mM also resulted in concentration-dependent increases in AR mRNA and enzyme activity that could be resolved into two components, one that was glucose specific and observed at pathophysiological concentrations (< 55 mM) and a second that was osmotically induced at high concentrations (> 55 mM) and which was not glucose specific. The present study demonstrates that pathophysiological levels of glucose specifically activate polyol metabolism with a consequent decrease in Na,K-ATPase activity in pancreatic duct epithelial cells, and that this response to hyperglycemia could contribute to decreased pancreatic secretion observed in IDDM. This is the first report of AR regulation in the pancreatic duct epithelium. (J. Clin. Invest. 1997. 100: 1685–1692.) Key words: bicarbonate secretion • diabetes mellitus • osmotic regulation • gene regulation • polyol metabolism

Introduction

Several clinical studies (1–4) have demonstrated that fluid and bicarbonate secretion by epithelial cells of the pancreatic exocrine duct system is impaired in 40–80% of patients with insulin-dependent diabetes mellitus (IDDM), although the pathogenic mechanisms through which pancreatic duct secretion is compromised in diabetes remain unknown. Studies in a variety of other end organs affected by diabetes, including peripheral nerve, retina, kidney, and vascular smooth muscle cells have demonstrated that a hyperglycemia-induced decrease in Na,K-ATPase activity could contribute to the development of diabetic complications (5–9). Na,K-ATPase exchanges intracellular Na+ for extracellular K+, thereby generating the electrochemical gradients that are essential for vectorial transport of water and electrolytes across epithelia. In pancreatic duct cells, an inwardly directed Na+ electrochemical gradient created by Na,K-ATPase provides the driving force for H+ extrusion and HCO3− uptake, the essential transport steps underlying bicarbonate secretion (reviewed in references 10, 11). A decrease in the activity of Na,K-ATPase in pancreatic duct cells thus could result in the diminution of bicarbonate output clinically observed in diabetic patients.

Inhibition of Na,K-ATPase activity in diabetes is believed to be linked to increased flux of glucose through the polyol metabolic pathway (5, 6, 7, 12). Aldose reductase (AR), which catalyzes the reduction of glucose to sorbitol, is a central enzyme of polyol metabolism. AR has been implicated by both clinical and basic research in the development of diabetic complications for more than a quarter of a century (13). AR inhibitors have been shown to normalize Na,K-ATPase activity in peripheral nerve (14) and to improve nerve conduction velocity and nerve repair/regeneration in diabetic rats (15). Renal tissues in diabetic rats also have been shown to have increased AR mRNA levels, immunoreactivity, and enzyme activity (16). A correlation between the development of diabetic retinopathy and expression of AR in the retinal pigment epithelium of human diabetic subjects also has been demonstrated (17).

Despite evidence for pancreatic duct dysfunction in IDDM, there is no information available on the regulation of polyol metabolism or Na,K-ATPase in pancreatic duct epithelial cells in diabetes. The present studies were therefore undertaken to analyze AR expression in the Capan-1 human pancreatic duct adenocarcinoma cell line. Transformed cell lines have been previously successfully used as in vitro models to study polyol-related diabetic complications (18). Capan-1 cells remain well differentiated in culture (19–22) and express several essential pancreatic duct enzymes and transporters including alkaline phosphatases (19–21), carbonic anhydrase IV (21) and the cystic fibrosis transmembrane regulator (CFTR) (19, 20). When cultured in a three-dimensional connective tissue matrix, Capan-1 cells form polarized duct-like structures (21). Individual

Portions of this work have appeared in abstract form at the American Pancreatic Association meeting, 7–8 November 1996 in Chicago, IL and at the American Diabetes Association meeting, 21–24 June 1997 in Boston, MA.

Address correspondence to Douglas N. Henry, Department of Physiology, Michigan State University, 108 Gillner Hall, East Lansing, MI 48824-1101. Phone: 517-355-6475 ext. 1278; FAX: 517-355-5125; E-mail: henry@psl.msu.edu

Received for publication 26 February 1997 and accepted in revised form 14 August 1997.

J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/97/10/1685/08 $2.00
Volume 100, Number 7, October 1997, 1685–1692 http://www.jci.org

1. Abbreviations used in this paper: AR, aldose reductase; IDDM, insulin-dependent diabetes mellitus; PKC, protein kinase C; ORE, osmotic response element.
cells exhibit apical microvilli and abundant basolateral membrane folds, hallmarks of differentiated transporting epithelial cells. The Capan-1 cell line thus provides a good in vitro pancreatic duct epithelial model with a well-preserved native phenotype. In the current studies, the effects of hyperglycemia on AR mRNA expression and enzyme activity and Na,K-ATPase activity were measured in Capan-1 cells. Results demonstrate that Capan-1 cells express AR and that it is inducible by both pathophysiological and hyperosmolar concentrations of glucose. Glucose-specific induction of AR was detected in the pathophysiological range of glucose concentrations. Inhibition of Na,K-ATPase activity by pathophysiological concentrations of glucose was also detected in Capan-1 cells. These studies support the hypothesis that pancreatic duct cells undergo a glucose-induced activation of polyol metabolism in IDDM that may lead to inhibition of Na,K-ATPase activity and, consequently, to diminution of bicarbonate output.

Methods

Reagents and supplies. RPMI-1640 culture medium, antibiotics, HBSS, and trypsin were obtained from GIBCO BRL (Gaithersburg, MD); fetal calf serum from Hyclone Labs (Logan, UT); culture dishes, and flasks from Falcon (Becton-Dickinson & Co., Lincoln Park, NJ), and glucose, mannitol, 3-O-methylglucose (tissue culture grade) and all other commonly used chemicals and reagents from Sigma Chemical Co. (St. Louis, MO). α-32P dCTP was from DuPont NEN (Boston, MA).

Cell culture techniques. The present study utilized the Capan-1 human pancreatic duct adenocarcinoma cell line (HTB-79) obtained from the American Type Culture Collection (Rockville, MD). Capan-1 cells were cultured in RPMI-1640 medium supplemented with 15% fetal calf serum and 1% penicillin/streptomycin and 5.5 mM glucose. Capan-1 cells were passaged at a density of 40–100,000 cells/cm² in 75-cm² flasks. Cells were plated to yield near-confluent cultures at the end of 24–168-h experiments. 10-cm dishes were used throughout the study. The freshly plated cells were allowed to attach in standard growth medium for at least 24 h before incubation for various periods in different concentrations of glucose, mannitol, or 3-O-methylglucose.

Na,K-ATPase activity. For determination of the effect of elevated glucose on Capan-1 cell Na,K-ATPase activity, cells were grown for 72 h in 5.5 and 22 mM glucose until nearly confluent. Each plate of cells was rinsed twice with 5.0 ml of HBSS, then once with 5.0 ml of cold ATPase homogenizing medium (250 mM sucrose, 0.25 mM EDTA, and 20 mM imidazole, pH 7.2). The cells were then scraped from the plate in 1.0 ml of cold homogenizing medium and transferred to a ground glass homogenizer in which they were disrupted with 15 strokes. Duplicate samples (100 µl) were incubated for 20 min at 37°C in 1.4 ml of ATPase reaction medium consisting of (in mM): 5.0 NaCl, 20 KCl, 5 MgCl₂, 30 imidazole (pH 7.2), <0.5 µM ouabain. Reactions were terminated by the addition of 2.5 ml of cold 10% trichloroacetic acid. Inorganic phosphate liberated from ATP during the reaction was determined by the procedure of Peterson (23) and normalized to homogenate protein as determined by the Coomassie blue binding assay (24). Na,K-ATPase activity was calculated as the ouabain-sensitive portion of ATP hydrolysis. Results were expressed as µmol of Pi/mg protein per h.

Immunoblotting of Na,K-ATPase and AR. The effect of elevated glucose on Capan-1 cell Na,K-ATPase and AR protein levels were determined by quantitative immunoblotting using well-characterized antisera raised against the catalytic subunit of Na,K-ATPase (25) and human placental AR (26). 300-µl aliquots of Capan-1 cell homogenate prepared as described for Na,K-ATPase assay were mixed with 150 µl of SDS-containing sample buffer, heated at 95°C for 5 min, mixed with 50 µl of 20% β-mercaptoethanol, and stored at −20°C. After thawing, samples corresponding to 10 µg of cell protein per lane were electrophoresed on 7.5% linear polyacrylamide mini-gels. The separated proteins were then transferred to nitrocellulose sheets by conventional procedures (27). The transferred Na,K-ATPase catalytic subunit or AR protein was visualized by incubation for 2 h at 23°C in PBS containing a 1:400 dilution of the primary anti-Na,K-ATPase or anti-AR antibody, followed by a 90-min incubation at 23°C in PBS containing a 1:400 dilution of a commercial immunoglobulin-ulin-peroxidase conjugate (Sigma Chemical Co.). After development for peroxidase reactivity, blots were quantitated by scanning densitometry using a high resolution AGFA® optical scanner and National Institutes of Health (NIH) Image software.

AR mRNA expression. AR mRNA levels were measured by Northern and dot blot analysis. Total RNA from Capan-1 cells grown in 5.5, 11, 22, 33, 55, 77, and 110 mM glucose for 0–168 h was obtained by a modification of the acid-phenol extraction method and 10 µg of RNA were resolved on denaturing 2.2 M formaldehyde-1% agarose gels (28). After electrophoresis, RNA was transferred to ZetaBind® nylon filters (CUNO, Inc., Meriden, CT) by capillary blotting. Filters were stained with methylene blue to examine the integrity of the RNA and to assess the uniformity of loading and transfer. Dot blot analysis was performed with serial dilutions of RNA applied to ZetaBind® nylon filters using a vacuum manifold. The filters were fixed and hybridized at high stringency (29). Human retinal AR cDNA consisting of exons 2 to 6 was used for making AR probes (28). Chicken β-actin cDNA (30) was used for making β-actin probes. The probes were labeled with 32P-dCTP using random primers to a specific activity of 10⁹ dpm/mg and separated from unincorporated nucleotides by gel filtration. After 18 h, hybridized filters were washed at high stringency (29). Autoradiograms were obtained with multiple exposures to remain within the linear range of the film and were quantitated by scanning densitometry using a high resolution AGFA® optical scanner and NIH Image software. Each blot was serially hybridized with both AR and β-actin. Filters were stripped until free of radioactivity before rehybridization.

AR activity. AR activity was assessed spectrophotometrically (31) at 30°C by monitoring the decrease in absorbance of NADPH at 340 nm for 10 min in the absence and presence of 10 mM glyceraldehyde as a substrate. Enzyme activity was normalized to supernatant protein content and expressed as nmol NADPH oxidized/mg protein per min. Supernatant protein content was measured using the bichoninic acid (BCA) protein assay reagent (Pierce, Rockford, IL).

Statistical analysis. Results are expressed as means±SE of at least four experiments. Statistical significance of differences between experimental groups was determined using Student’s t tests.

Results

Glucose-induced decrease in Na,K-ATPase activity in Capan-1 cells. ATPase activities, both ouabain sensitive (Na,K-ATPase) and ouabain insensitive (Mg-ATPase), were determined in Capan-1 cells cultured in normal (5.5 mM) and pathophysiological (22 mM) concentrations of glucose for 72 h. A statistically significant (P < 0.01) decrease in Na,K-ATPase activity was seen in 22 mM glucose (Fig. 1A). That this effect was selective for Na,K-ATPase is indicated by the observation that ouabain-insensitive Mg-ATPase activity was not significantly altered by incubation in 22 mM glucose (Fig. 1B). It has been shown in nerve, renal, and retinal tissue that hyperglycemia-induced inhibition of Na,K-ATPase activity is due to increased flux of glucose through the polyol metabolic pathway (5–7). To test whether a similar mechanism is involved in the observed inhibition of Na,K-ATPase in Capan-1 cells, we attempted to reverse the inhibition of Na,K-ATPase with sorbinil, a specific inhibitor of AR. All sorbinil experiments were carried out in serum- and antibiotic-free medium to prevent binding and inactivation of sorbinil by serum pro-
Glucose Regulates Aldose Reductase in Capan-1 Cells

To make sure that serum- and antibiotic-free medium does not affect Na,K-ATPase activity, an additional control experiment was performed. The cells were incubated in serum- and antibiotic-free media containing 5.5 or 22 mM glucose with or without 100 µM sorbinil for 72 h, at which time Na,K-ATPase and Mg-ATPase activities were determined. Addition of 100 µM sorbinil completely reversed the decrease in Na,K-ATPase activity induced by 22 mM glucose (Fig. 1 A).

To determine whether the change in Na,K-ATPase activity observed was due to changes in enzyme expression, changes in the kinetic properties of the enzyme, or both, the levels of Capan-1 Na,K-ATPase protein were assessed by quantitative immunoblotting. The primary antibody reacted with a single protein of approximately 97,000 mol. wt. in Capan-1 cells cultured in both 5.5 and 22 mM glucose (Fig. 2 A). Densitometric analysis of blots from four preparations of Capan-1 cells cultured in each of the two concentrations showed no significant difference in Na,K-ATPase expression (4,820±433 arbitrary densitometry units at 5.5 mM vs. 5,010±564 U at 22 mM; mean±SE, Fig. 2 B). These results indicate that the observed decrease in activity is due to changes in the kinetic properties of the enzyme rather than to a decrease in enzyme abundance.

**Effect of glucose on AR mRNA expression in Capan-1 cells.** As noted above, AR is a key enzyme of polyol metabolism, and has been implicated in the development of diabetic complications in retinal, renal, nerve, and vascular smooth muscle tissue. It is not known whether pancreatic duct cells express AR and, if so, whether expression of the enzyme is al-

---

**Figure 1.** Effect of increased glucose on ATPase activity in Capan-1 cells. Na,K-ATPase (A) and Mg-ATPase (B) activities were measured in Capan-1 cells cultured in normal (5.5 mM, open bars) and in pathophysiological (22 mM, hatched bars) concentrations of glucose for 72 h in media containing 15% FCS and penicillin/streptomycin (P/S), in media without serum and antibiotics and in media without serum and antibiotics containing 100 µM sorbinil as indicated. *P < 0.01 compared to value in 5.5 mM glucose. **P < 0.01 compared to value in 22 mM glucose without sorbinil. Results represent means±SE of five to eight experiments.

**Figure 2.** Na,K-ATPase protein expression in Capan-1 cells cultured in different glucose concentrations. (A) Immunoblots of Na,K-ATPase protein from Capan-1 cells cultured in normal (5.5 mM) and in pathophysiological (22 mM) concentrations of glucose for 72 h. (B) Quantitation of Na,K-ATPase protein expression from immunoblots. Results represent means±SE of density determinations from four immunoblots in each group.
tered by glucose. To address these questions, AR mRNA expression in Capan-1 cells exposed for 24 h to glucose concentrations ranging from 5.5 to 110 mM was determined. Northern blot analysis demonstrated that AR cDNA hybridized to a single band of an appropriate size (~1.8 kb) for the AR mRNA transcript. (B) Dot blot quantitation of AR mRNA expression in Capan-1 cells cultured in 5.5–110 mM glucose for 24 h. The data were normalized to β-actin mRNA expression. *P < 0.05 in 11–110 mM glucose vs. 5.5 mM glucose. Results represent means±SE of four experiments.

Time course of AR mRNA induction in Capan-1 cells. The time dependence of AR mRNA induction was determined in Capan-1 cells exposed to 110 mM glucose, a concentration that caused nearly maximal induction of AR mRNA in dose-response experiments. The increase in AR mRNA level was first detected after 8 h of exposure to 110 mM glucose and reached a maximal steady-state level after 24 h, which was maintained for up to 168 h (Fig. 4, A and B).

Effect of glucose on AR protein expression and enzyme activity. To further elucidate the effect of glucose on activation
of polyol metabolism in Capan-1 cells, we determined whether the observed AR mRNA induction by glucose was accompanied by an increase in AR protein expression and enzyme activity. Both AR protein expression (Fig. 5) and enzyme activity (Fig. 6) in Capan-1 cells cultured in 5.5–110 mM glucose for 72 h were increased in parallel after AR mRNA induction. An increase in AR enzyme activity was first detected after 24 h of exposure to 110 mM glucose and reached a maximal level after 48 h (Fig. 7). Thus, the 110 mM glucose-induced increase in AR mRNA expression was followed within 24 h by an increase in AR enzyme activity in Capan-1 cells.

**Substrate specificity of AR mRNA induction.** To determine whether the observed increase in AR mRNA expression and enzyme activity was caused by an increase in glucose metabolism, glucose transport, or by osmotic stress, Capan-1 cells were exposed to mannitol, an osmotically active hexose sugar that does not undergo facilitated transport, and to 3-O-methylglucose, a transportable, but nonmetabolizable glucose analog. In contrast to glucose, neither 22 mM mannitol nor 22 mM 3-O-methylglucose induced AR mRNA expression (Fig. 8 A) or enzyme activity (Fig. 8 B). Moreover, inhibition of AR mRNA

---

**Figure 6.** Effect of glucose on AR enzyme activity in Capan-1 cells. AR enzyme activity was measured in Capan-1 cells exposed to 5.5–110 mM glucose for 72 h. *P < 0.05 in 22–110 mM vs. 5.5 mM glucose. Results represent means±SE of 10 experiments.

**Figure 7.** Time dependence of the effect of glucose on AR enzyme activity in Capan-1 cells. AR enzyme activity was measured in Capan-1 cells exposed to 110 mM glucose for 0–72 h. *P < 0.05 in 24–72 h vs. 0 h. Results represent means±SE of six experiments.

**Figure 8.** Glucose-specific induction of AR mRNA and enzyme activity in Capan-1 cells. (A) Dot blot quantitation of AR mRNA expression in Capan-1 cells exposed to pathophysiological (22 mM) or hyperosmolar (110 mM) concentrations of glucose (hatched bar), mannitol (open bar), and 3-O-methylglucose (black bar). *P < 0.05 compared to control (5.5 mM glucose) value. Results represent means±SE of four experiments. (B) AR enzyme activity in Capan-1 cells cultured as in Fig. A. *P < 0.05 compared to control (5.5 mM glucose) value. Results represent means±SE of eight experiments.
expression and enzyme activity was detected when cells were exposed to 22 mM 3-O-methylglucose compared to the control levels of glucose (5.5 mM). When concentrations of mannitol and 3-O-methylglucose were increased to 110 mM, each caused AR mRNA induction (Fig. 8A) and an increase in enzyme activity (Fig. 8B). However, the degree of AR induction was substantially lower in 110 mM mannitol than in 110 mM glucose and even lower in 110 mM 3-O-methylglucose.

Discussion

The present study used the human pancreatic duct adenocarcinoma cell line, Capan-1, as an in vitro model to analyze the effects of hyperglycemia on the pancreatic duct system. Capan-1 cells represent a well differentiated cell line of ductal origin (19–22). In the present study we have shown that Capan-1 cells also express Na,K-ATPase and AR, and that the activities of both enzymes can be altered by hyperglycemia.

An increase in medium glucose concentration in the pathophysiological range significantly inhibited Na,K-ATPase activity in Capan-1 cells. In pancreatic duct cells, the Na⁺ electrochemical gradient created by Na,K-ATPase drives H⁺ extrusion and HCO₃⁻ uptake, the important steps for vectorial bicarbonate secretion (10, 11). A hyperglycemia-induced reduction in Na,K-ATPase activity of the magnitude observed in the current studies might, therefore, result in a decreased ability of the pancreatic duct system to secrete fluid and bicarbonate. Whether a comparable decrease in enzyme activity occurs in the pancreatic ducts of patients with IDDM is unknown, although the possibility is supported by recent studies in our laboratory which demonstrated that Na,K-ATPase activity was decreased 76% in pancreatic ducts isolated from guinea pigs with streptozotocin-induced diabetes (32).

There has been no information available on the pathogenic mechanisms through which glucose may cause inhibition of Na,K-ATPase activity in pancreatic duct cells, although studies on other tissues have demonstrated that hyperglycemia-induced inhibition of Na,K-ATPase activity in diabetes is linked to increased AR-mediated flux of glucose through the polyl metabolic pathway (5–7, 12). In the present study, we demonstrated for the first time that pancreatic duct cells express AR and that it is inducible by both pathophysiologically and hyperosmolar concentrations of glucose. AR mRNA and protein expression as well as AR enzyme activity were increased by glucose in Capan-1 cells. Moreover, sorbinil, a specific inhibitor of AR, reversed the decrease in Na,K-ATPase induced by 22 mM glucose. These data directly demonstrate that glucose-induced activation of AR leads to inhibition of Na,K-ATPase in Capan-1 cells.

The regulation of AR has been best described in renal medullary tissue, which faces extracellular hyperosmosality during urinary concentration (33–37). AR in renal medullary cells works as a part of a physiological osmoregulatory mechanism to adjust intracellular osmolality by accumulation of the nonionic, organic intracellular osmolyte sorbitol. The mechanism through which extracellular osmolality in the renal medulla regulates AR activity was recently shown to involve activation of an osmotic response element (ORE) of the AR gene, an 11-bp nucleotide sequence located 3.7 kb upstream from the transcription initiation site that mediates hypertonicity-responsive enhancer activity (38). It is not known whether the same mechanism is involved in AR regulation in end organs affected by diabetes. Levels of glucose sufficient to substantially raise serum osmolarity are not sustained in diabetes. Thus, high osmolarity probably does not account for the activation of AR outside of the renal medulla. In the present study, AR was specifically induced by pathophysiological concentrations of glucose. Mannitol, an osmotically active hexose sugar that does not undergo facilitated transport, and 3-O-methylglucose, a transportable, but nonmetabolizable glucose analog, were not effective inducers of AR in the pathophysiological range of concentrations. In addition, inhibition of AR mRNA expression and enzyme activity was detected in Capan-1 cells exposed to pathophysiological concentrations of 3-O-methylglucose. These results may be explained if 3-O-methylglucose competes with glucose for a common membrane transporter. In this case, an increase in 3-O-methylglucose concentration would lead to decreased glucose uptake and metabolism and consequently to a reduction of AR activity. These results suggest that nonosmotic, glucose-specific, induction of AR occurs in pancreatic duct cells exposed to pathophysiological concentrations of glucose. The mechanism of nonosmotic, glucose-specific, induction of AR remains unknown. Osmotic regulation of AR is also preserved in pancreatic duct cells, as mannitol and 3-O-methylglucose were effective inducers of AR at hyperosmolar concentrations.

The mechanism(s) through which an increase in AR activity may lead to inhibition of Na,K-ATPase activity in pancreatic duct cells is unknown. AR catalyzes the reduction of glucose to sorbitol, the accumulation of which has been postulated to alter the metabolism of myo-inositol, a six carbon cyclic polyl, in peripheral nerve, retina, and renal tissues (28, 39, 40). It has been demonstrated in nerve and retina that depletion of myo-inositol may reduce its incorporation into cellular phosphoinositol pools, resulting in tissue-specific changes in diacylglycerol (DAG), the chief physiological activator of protein kinase C (PKC) (39, 41). Increased oxidation of sorbitol to fructose also has been shown to alter cellular redox potential, resulting in an increase in the cytrosolic ratio of NADH/NAD⁺ in glomerular mesangial cells and microvasculature (42, 43). This change in redox potential can impact many cellular processes but, in particular, may cause increased de novo synthesis of DAG (43) leading to elevation of PKC activity.

That alterations in PKC activity may play a central role in diabetic complications is indicated by the observation by Ishii and coworkers (44) that vascular dysfunctions in diabetic rats could be ameliorated by oral administration of LY335351, a specific inhibitor of the β-2 isoform of PKC, and by studies of Na,K-ATPase levels in sciatic nerves of diabetic mice by Hermenegildo (45), which demonstrated that recovery of depressed Na,K-ATPase activity could be induced by administration of the PKC inhibitors, H7 and calphostin C. These studies suggest that PKC may be directly involved as a mediator of the decrease in Na,K-ATPase activity. This assumption is supported by the observations that PKC can phosphorylate the catalytic subunit of purified Na,K-ATPase (46) and that this phosphorylation inhibits the activity of the enzyme by as much as 50% (47). Middleton and coworkers (48) also have reported that phorbol ester activation of PKC in intact kidney epithelial cells inhibited Na,K-ATPase activity by 42% and phorbol esters have been reported to increase ³²P labeling of the catalytic subunit of Na,K-ATPase in sciatic nerves (49).

Xia and coworkers have recently demonstrated glucose-induced sequential activation of PKC and cytoplasmic phos-
phospholipase A2 (cPLA2), as well as increased release of AA and its metabolites and decreased Na,K-ATPase activity in cultured vascular smooth muscle cells (50). The increase in cPLA2 activity could be prevented by the PKC inhibitor, GFX, while A2COCF, a cPLA2 inhibitor, prevented the glucose-induced decrease in Na,K-ATPase activity. The authors concluded that hyperglycemia causes a chronic increase in PKC activity which activates cPLA2 by direct phosphorylation and that Na,K-ATPase activity is suppressed not by inhibitory phosphorylation of the enzyme by PKC, but by increased liberation of AA and its metabolites.

Hyperglycemia-induced activation of AR thus may result in chronic hyperstimulation of PKC, which may cause a decrease in Na,K-ATPase activity either by direct phosphorylation or through AA production. A reduction in the activity of this key transport protein could account for the decrease in pancreatic bicarbonate output clinically observed in diabetic patients. Results of the current studies support the hypothesis that hyperglycemia-induced activation of glycol metabolism may play a central role in the development of diabetic complications in pancreatic duct cells.

Acknowledgments

The anti-Na,K-ATPase antibody utilized in these studies was provided by Stephen A. Ernst, Ph.D., Department of Anatomy and Cell Biology, University of Michigan, Ann Arbor, MI. The anti-AR antibody was a generous gift from Peter F. Kador, Ph.D., Laboratory of Ocular Therapeutics, National Eye Institute, NIH, Bethesda, MD. Sorbinil was provided by Peter J. Oates, Ph.D., Central Research Division, Pfizer Inc. (Groton, CT).

This work was supported by National Institutes of Health (NIH) grant R01 DK46607 to S.R. Hootman and National Institutes of Health grant K11 DK02193, Juvenile Diabetes Foundation International Research Grant No. 195044 and GCRC grant M01-RR00042 to D.N. Henry.

References


